GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Jun 30, 2024

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-24-000085General Corporate
Debt relative to revenue35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

206.64% · OPTIONAL · VALID

Capex intensity90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.22% · OPTIONAL · VALID

Operating cash generation55thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

12.62% · OPTIONAL · VALID

Revenue growth60thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

18.44% · CORE · VALID

Inventory pressure50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

90.88% · OPTIONAL · VALID

Operating margin50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

3.74% · CORE · VALID

R&D intensity10thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

5.29% · OPTIONAL · VALID

SBC intensity85thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.70% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
207.71%
Current
206.64%
Delta
-1.07%
Capex Intensity Decreased
Previous
3.33%
Current
3.22%
Delta
-0.11%
Cash Generation Decreased
Previous
13.29%
Current
12.62%
Delta
-0.68%
Growth Decreased
Previous
28.70%
Current
18.44%
Delta
-10.26%
Inventory Pressure Increased
Previous
82.83%
Current
90.88%
Delta
8.05%
Profitability Decreased
Previous
14.78%
Current
3.74%
Delta
-11.04%
R And D Intensity Decreased
Previous
7.65%
Current
5.29%
Delta
-2.36%
Sbc Intensity Increased
Previous
5.05%
Current
5.70%
Delta
0.65%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.